Article info
Original research
Informed consent for early-phase clinical trials: therapeutic misestimation, unrealistic optimism and appreciation
- Correspondence to Prof. Jodi Halpern, School of Public Health, University of California, Berkeley 94704, USA; jhalpern{at}berkeley.edu
Citation
Informed consent for early-phase clinical trials: therapeutic misestimation, unrealistic optimism and appreciation
Publication history
- Received October 23, 2018
- Revised March 29, 2019
- Accepted April 16, 2019
- First published June 12, 2019.
Online issue publication
July 01, 2019
Article Versions
- Previous version (12 June 2019).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Phase 1 oncology trials and informed consent
- Unrealistic optimism and the ethics of phase I cancer research
- Two concepts of therapeutic optimism
- Understanding people’s ‘unrealistic optimism’ about clinical research participation
- Perceptions of control and unrealistic optimism in early-phase cancer trials
- Therapeutic appropriation: a new concept in the ethics of clinical research
- From protection to entitlement: selecting research subjects for early phase clinical trials involving breakthrough therapies
- Navigating choice in the face of uncertainty: using a theory informed qualitative approach to identifying potential patient barriers and enablers to participating in an early phase chimeric antigen receptor T (CAR-T) cell therapy trial
- Vulnerability, therapeutic misconception and informed consent: is there a need for special treatment of pregnant women in fetus-regarding clinical trials?
- Oncology patients’ experiences in experimental medicine cancer trials: a qualitative study